157 related articles for article (PubMed ID: 21110092)
1. Systemic mastocytosis presenting with acute oliguric renal failure: report of a case and review of the literature.
Moore AE; Johnston WH; Hever A; Peng S; Kujubu DA
Int Urol Nephrol; 2012 Apr; 44(2):639-42. PubMed ID: 21110092
[TBL] [Abstract][Full Text] [Related]
2. Papular-purpuric "gloves and socks" syndrome in systemic mastocytosis treated with imatinib: a diagnostic challenge.
Jaworek AK; Sacha T; Woźniak-Knop M; Hałubiec P; Giza A; Wojas-Pelc A
Pol Arch Intern Med; 2024 Jun; 134(6):. PubMed ID: 38640058
[No Abstract] [Full Text] [Related]
3. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
[TBL] [Abstract][Full Text] [Related]
5. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
[TBL] [Abstract][Full Text] [Related]
6. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
[TBL] [Abstract][Full Text] [Related]
7. Acute oliguric renal failure in HELLP syndrome: case report and review of literature.
Gupta A; Ferguson J; Rahman M; Weber-Shrikant E; Venuto R
Ren Fail; 2012; 34(5):653-6. PubMed ID: 22364519
[TBL] [Abstract][Full Text] [Related]
8. Imatinib for systemic mast-cell disease.
Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A
Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.
Jung AG; Horny HP; Sotlar K; Overbeck T; Schön MP; Lippert U
J Am Acad Dermatol; 2011 Jul; 65(1):224-6. PubMed ID: 21679828
[No Abstract] [Full Text] [Related]
10. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
[No Abstract] [Full Text] [Related]
11. Systemic Mastocytosis: documented pathologic response to imatinib.
Gollard RP; Ruemmler-Fish C; Garcia D
Eur J Haematol; 2007 Oct; 79(4):367-8. PubMed ID: 17655701
[No Abstract] [Full Text] [Related]
12. On being metachromatic: mystique and misunderstanding in mastocytosis.
Gotlib J
Am J Hematol; 2009 Dec; 84(12):779-81. PubMed ID: 19899132
[No Abstract] [Full Text] [Related]
13. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.
Lim KH; Pardanani A; Butterfield JH; Li CY; Tefferi A
Am J Hematol; 2009 Dec; 84(12):790-4. PubMed ID: 19890907
[TBL] [Abstract][Full Text] [Related]
14. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
[TBL] [Abstract][Full Text] [Related]
15. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
[No Abstract] [Full Text] [Related]
16. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.
Tefferi A; Pardanani A
Int J Hematol; 2004 Jun; 79(5):441-7. PubMed ID: 15239393
[TBL] [Abstract][Full Text] [Related]
17. Skin lesions and mast cells.
Blood; 2008 Jul; 112(1):28. PubMed ID: 18584778
[No Abstract] [Full Text] [Related]
18. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.
Alvarez-Twose I; González P; Morgado JM; Jara-Acevedo M; Sánchez-Muñoz L; Matito A; Mollejo M; Orfao A; Escribano L
J Clin Oncol; 2012 Apr; 30(12):e126-9. PubMed ID: 22370312
[No Abstract] [Full Text] [Related]
19. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.
Merante S; Chichino G; Boveri E; Gottardi E; Soverini S; Cilloni D; Martinelli G
J Clin Oncol; 2006 Feb; 24(4):e6-7. PubMed ID: 16446324
[No Abstract] [Full Text] [Related]
20. Acute kidney injury presenting a feature of leukemic infiltration during therapy for chronic myelogenous leukemia.
Yuzawa Y; Sato W; Masuda T; Hamada Y; Tatematsu M; Yasuda Y; Ozaki T; Ito I; Mizuno M; Maruyama S; Ito Y; Matsuo S
Intern Med; 2010; 49(12):1139-42. PubMed ID: 20558931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
